Pfizer beat fourth-quarter estimates as Covid sales fell, pointing to obesity trial progress and cost cuts in its post-Covid ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...

Feb 3(Reuters) - Pfizer on Tuesday reported fourth-quarter earnings above Wall Street estimates, as sustained demand for ...

Pfizer (PFE) stock drops as analysts weigh in on mid-stage trial data for the company's obesity drug and its Q4 2025 earnings. Read more here.

Pfizer PFE reported fourth-quarter 2025 adjusted earnings per share of 66 cents, which comprehensively beat the Zacks Consensus Estimate of 57 cents per share. Earnings rose 5% year over year.

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

To help answer common vaccine questions, we consulted Dr. Stanley Perlman, a professor at the University of Iowa’s Carver ...

PFE stock​ today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...